QI
BTAI icon

QS Investors’s BioXcel Therapeutics BTAI Stock Holding History

QS Investors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-325
Closed -$240K – 1190
2020
Q4 		$240K Buy
+325
New +$253K ﹤0.01% 1063
2020
Q3 		– Sell
-1,099
Closed -$933K – 1226
2020
Q2 		$933K Buy
+1,099
New +$717K 0.01% 738

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QS Investors's BTAI Position: Q1 2021 in Review

QS Investors sold out of BioXcel Therapeutics (BTAI) in Q1 2021, closing a stake of 325 shares — an estimated $240K sold.

QS Investors first reported a position in BTAI in Q2 2020 and held it in 2 quarters. The position peaked at $933K in Q2 2020. 116 funds tracked by Wall St. Rank hold BTAI as of Q1 2021.

  • QS Investors reported no remaining BioXcel Therapeutics position as of Q1 2021 after selling out during the quarter.
  • QS Investors sold 325 BioXcel Therapeutics shares in Q1 2021, an estimated $240K.
  • QS Investors first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 2 quarters.
  • QS Investors's BioXcel Therapeutics position peaked at $933K in Q2 2020.
  • 116 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2021.

Based on QS Investors's 13F filing for Q1 2021, filed 13 May 2021.